Published in N Engl J Med on August 09, 2007
A multicentre randomized trial of the treatment of patients with pemphigus vulgaris with infliximab and prednisone compared with prednisone alone. Br J Dermatol (2015) 1.46
Looking forward to new targeted treatments for chronic spontaneous urticaria. Clin Transl Allergy (2017) 1.39
Desmoglein as a target in skin disease and beyond. J Invest Dermatol (2011) 1.28
Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res (2009) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare. Br Dent J (2015) 1.13
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
Homologous regions of autoantibody heavy chain complementarity-determining region 3 (H-CDR3) in patients with pemphigus cause pathogenicity. J Clin Invest (2010) 0.99
Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients. Arch Dermatol (2012) 0.95
Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm (2015) 0.94
Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years. J Invest Dermatol (2014) 0.91
Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol (2009) 0.89
Targeted immunotherapy with rituximab leads to a transient alteration of the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract (2010) 0.89
Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol (2013) 0.88
Novel targeted therapies for autoimmunity. Curr Opin Immunol (2009) 0.87
Advances in pemphigus and its endemic pemphigus foliaceus (Fogo Selvagem) phenotype: a paradigm of human autoimmunity. J Autoimmun (2008) 0.86
B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism. Clin Exp Immunol (2011) 0.86
Long-lived plasma cells and memory B cells produce pathogenic anti-GAD65 autoantibodies in Stiff Person Syndrome. PLoS One (2010) 0.85
mTOR has distinct functions in generating versus sustaining humoral immunity. J Clin Invest (2016) 0.84
Management of pemphigus. F1000Prime Rep (2014) 0.84
Challenges in the pursuit of immune tolerance. Immunol Rev (2011) 0.83
Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep (2008) 0.82
Rituximab and pemphigus--a therapeutic advance. N Engl J Med (2007) 0.81
Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb) (2012) 0.78
Monoclonal anti-CD20 Antibody Therapy in Cicatrical Pemphigoid with Oral and Hypopharyngeal Involvement and Related Conditions. J Clin Aesthet Dermatol (2013) 0.78
Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol (2015) 0.77
Seeking approval: present and future therapies for pemphigus vulgaris. Curr Opin Investig Drugs (2008) 0.77
Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol (2015) 0.77
Rituximab for autoimmune blistering diseases: recent studies, new insights. G Ital Dermatol Venereol (2012) 0.77
Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab. An Bras Dermatol (2013) 0.76
Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus. J Allergy Clin Immunol (2012) 0.76
Rituximab in severe skin diseases: target, disease, and dose. Clin Pharmacol (2010) 0.76
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. Case Rep Dermatol (2017) 0.75
Update on the use of rituximab for intractable rheumatoid arthritis. Open Access Rheumatol (2009) 0.75
Management of Pemphigus Vulgaris. Adv Ther (2016) 0.75
Rituximab therapy in pemphigus and other autoantibody-mediated diseases. F1000Res (2017) 0.75
Rituximab therapy improves recalcitrant Pemphigus vulgaris. EXCLI J (2015) 0.75
B cell depletion in autoimmune diabetes: insights from murine models. Expert Opin Ther Targets (2011) 0.75
Incidence of bullous pemphigoid and pemphigus vulgaris. BMJ (2008) 0.75
Successful treatment of severe anti-p200 pemphigoid in a heart transplant recipient with a single cycle of rituximab. JAAD Case Rep (2017) 0.75
Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight (2017) 0.75
Rituximab: A Magic Bullet for Pemphigus. J Clin Diagn Res (2017) 0.75
Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med (2002) 5.58
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
The DRESS syndrome: a literature review. Am J Med (2011) 5.13
Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med (2008) 3.85
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol (2007) 3.58
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature (2013) 3.14
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med (2009) 3.13
Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 3.04
Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol (2007) 2.90
Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol (2003) 2.83
Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. Nat Genet (2007) 2.75
Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol (2007) 2.71
IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol (2010) 2.67
A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods (2008) 2.56
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol (2002) 2.49
Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol (2004) 2.33
Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med (2010) 2.28
Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol (2011) 2.27
Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol (2011) 2.19
Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol (2005) 2.15
Hearing thresholds and tympanic membrane sequelae in children managed medically or surgically for otitis media with effusion. Arch Pediatr Adolesc Med (2005) 2.13
Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med (2012) 2.12
B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol (2008) 2.10
Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol (2011) 2.03
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol (2007) 2.00
The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol (2015) 1.98
Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol (2003) 1.94
Identification of mutations in a new gene encoding a FERM family protein with a pleckstrin homology domain in Kindler syndrome. Hum Mol Genet (2003) 1.94
Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol (2012) 1.94
Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins (2003) 1.93
A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics (2008) 1.92
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther (2006) 1.90
Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol (2009) 1.87
HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci U S A (2013) 1.85
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol (2008) 1.81
TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol (2006) 1.79
Defining early mycosis fungoides. J Am Acad Dermatol (2005) 1.78
A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest (2005) 1.77
Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) (2009) 1.76
Human anti-HIV-neutralizing antibodies frequently target a conserved epitope essential for viral fitness. J Exp Med (2010) 1.74
Poor benefit/risk balance of intravenous immunoglobulins in DRESS. Arch Dermatol (2012) 1.71
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J Clin Invest (2007) 1.67
Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol (2009) 1.66
ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol (2009) 1.62
Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol (2011) 1.60
Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol (2008) 1.54
Toll-like receptors 2-deficient mice are protected against postischemic coronary endothelial dysfunction. Arterioscler Thromb Vasc Biol (2007) 1.54
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol (2003) 1.53
Role of TLR9 in anti-nucleosome and anti-DNA antibody production in lpr mutation-induced murine lupus. J Immunol (2006) 1.51
Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol (2008) 1.50
Brain magnetic resonance imaging in patients with Cowden syndrome. Medicine (Baltimore) (2005) 1.50
High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet (2013) 1.50
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119). J Infect Dis (2009) 1.49
Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol (2013) 1.49
Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol (2008) 1.47
Randomized, double-blind, multicenter study of the polymer-based 17-beta estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. Catheter Cardiovasc Interv (2007) 1.44
Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study. J Invest Dermatol (2007) 1.41
Sweet's syndrome after BCG vaccination. Acta Derm Venereol (2002) 1.41
Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum (2002) 1.41
Use of high-dose immunoglobulins in dermatology. J Dtsch Dermatol Ges (2009) 1.40
B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol (2010) 1.39
Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol (2009) 1.39
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer (2006) 1.38
Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1. PLoS Pathog (2010) 1.37
Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum (2011) 1.36
Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol (2007) 1.36
Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J (2002) 1.35
Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol (2005) 1.33